Janssen-Cilag International N.V

FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria

FDA · rheumatoid arthritis · 6 min

The FDA approved Immgolis and Immgolis Intri as the first interchangeable biosimilars to Janssen’s Simponi and Simponi Aria. The decision covers rheumatoid arthritis and ulcerative colitis and creates a new catalyst for BD teams and investors tracking golimumab competition.